Trademark Overview
On Wednesday, February 26, 2025, a trademark application was filed for LYBLOQEM with the United States Patent and Trademark Office. The USPTO has given the LYBLOQEM trademark a serial number of 99057068. The federal status of this trademark filing is NEW APPLICATION - RECORD INITIALIZED NOT ASSIGNED TO EXAMINER as of Wednesday, February 26, 2025. This trademark is owned by Pfizer Inc.. The LYBLOQEM trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, bone growth disorders, skin disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations, namely, anti-infective preparations, medicated dermatological preparations and smoking cessation preparations; vaccines for human use.
